Achieve Life SciencesACHV
Market Cap: 169M
About: Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Employees: 22
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
620% more call options, than puts
Call options by funds: $1.63M | Put options by funds: $226K
478% more capital invested
Capital invested by funds: $11.2M [Q4 2023] → $64.9M (+$53.7M) [Q1 2024]
200% more funds holding in top 10
Funds holding in top 10: 0 [Q4 2023] → 2 (+2) [Q1 2024]
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
37% more funds holding
Funds holding: 30 [Q4 2023] → 41 (+11) [Q1 2024]
35.18% more ownership
Funds ownership: 12.88% [Q4 2023] → 48.06% (+35.18%) [Q1 2024]
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Research analyst outlook
4 Wall Street Analysts provided 1 year price forecasts over the past 6 months
4 analyst ratings
Oppenheimer Francois Brisebois | 123%upside $11 | Outperform Maintained | 13 May 2024 |
JonesTrading Justin Walsh | 306%upside $20 | Buy Initiated | 17 Apr 2024 |
Oppenheimer Francois Brisebois | 265%upside $18 | Outperform Reiterated | 1 Apr 2024 |
Lake Street Thomas Flaten | 123%upside $11 | Buy Maintained | 5 Mar 2024 |
Financial journalist opinion
Based on 3 articles about ACHV published over the past 30 days